

Cover Story
NCI Director's Report
By Matthew Bin Han Ong
The gridlock in Washington is taking a toll on federally funded cancer research as the partisan wrangling in Congress over border security and funding for Israel and Ukraine shows no sign of relenting.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for December 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
- AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG